Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease

Huma Saeed, Luis Antonio Díaz, Antonio Gil-Gómez, Jeremy Burton, Jasmohan S. Bajaj, Manuel Romero-Gomez, Marco Arrese, Juan Pablo Arab, Mohammad Qasim Khan

Clin Mol Hepatol. 2025;31(Suppl):S94-S111. Published online November 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0811

View: 3692 Download: 307 Crossref: 4

Correspondence

Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: a systematic review and meta-analysis”

Ji Won Han, Dae Won Jun

Clin Mol Hepatol. 2025;31(2):e152-e154. Published online December 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.1160

View: 500 Download: 25

Editorial

A leap in the dark: Bariatric surgery for treatment of metabolic dysfunction-associated steatotic liver disease related cirrhosis: Editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Jing Zeng, Jian-Gao Fan

Clin Mol Hepatol. 2025;31(2):610-614. Published online December 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.1099

View: 588 Download: 37 Crossref: 2

Stabilizing hepatic fatty acid oxidation: Editorial on “USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination”

Myeung Gi Choi, Na Young Lee, Ja Hyun Koo

Clin Mol Hepatol. 2025;31(2):592-595. Published online November 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0971

View: 767 Download: 58

Correspondence

PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”

Baokai Sun, Likun Zhuang

Clin Mol Hepatol. 2025;31(1):e67-e69. Published online September 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0744

View: 933 Download: 75

Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis”

Young Eun Chon, Jung Hwan Yu, Seung Up Kim

Clin Mol Hepatol. 2025;31(1):e61-e63. Published online October 15, 2024

DOI: https://doi.org/10.3350/cmh.2024.0878

View: 888 Download: 28

Letter to the Editor

Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes

Meng-Yuan Miao, Jie-Qiong Lyu, Wei Jiang, Zhong-Yue Liu, Guo-Chong Chen

Clin Mol Hepatol. 2025;31(1):e35-e38. Published online September 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0719

View: 1049 Download: 65 Web of Science: 1 Crossref: 1

Editorial

TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”

Andrea Caddeo, Rosellina M. Mancina

Clin Mol Hepatol. 2025;31(1):293-296. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0703

View: 1134 Download: 101 Crossref: 2

Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”

Won Sohn

Clin Mol Hepatol. 2025;31(1):277-280. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0823

View: 1066 Download: 37 Crossref: 1

Original Article

Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis

Nicholas A. Rouillard, Scott D. Barnett, Xinrong Zhang, Leslie Kam, Richie Manikat, Ramsey Cheung, Mindie H. Nguyen

Clin Mol Hepatol. 2025;31(1):227-239. Published online November 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0564

View: 1622 Download: 134 Crossref: 6

Review

Bioactive metabolites: A clue to the link between MASLD and CKD?

Wen-Ying Chen, Jia-Hui Zhang, Li-Li Chen, Christopher D. Byrne, Giovanni Targher, Liang Luo, Yan Ni, Ming-Hua Zheng, Dan-Qin Sun

Clin Mol Hepatol. 2025;31(1):56-73. Published online October 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0782

View: 2128 Download: 183

Roles of X-box binding protein 1 in liver pathogenesis

Jihoon Tak, Yun Seok Kim, Sang Geon Kim

Clin Mol Hepatol. 2025;31(1):1-31. Published online October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0441

View: 2334 Download: 173

Reply to Correspondence

Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”

Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan

Clin Mol Hepatol. 2024;30(4):1039-1041. Published online September 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0801

View: 1142 Download: 26

Correspondence

The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease”

Yiyuan Zheng, Zhekun Xiong, Lina Zhao, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Fengbin Liu, Yong Li

Clin Mol Hepatol. 2024;30(4):1019-1022. Published online July 8, 2024

DOI: https://doi.org/10.3350/cmh.2024.0471

View: 1685 Download: 60

Original Article

TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD

Baokai Sun, Xiaoqian Ding, Jie Tan, Jie Zhang, Xueru Chu, Shuimi Zhang, Shousheng Liu, Zhenzhen Zhao, Shiying Xuan, Yongning Xin, Likun Zhuang

Clin Mol Hepatol. 2024;30(4):863-882. Published online July 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0268

View: 2681 Download: 264 Web of Science: 5 Crossref: 4

Editorial

Ursolic acid: A promising therapeutic agent for metabolic dysfunction-associated steatotic liver disease via inhibition of SPP1-induced Th17 cell differentiation: Editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease”

So Jung Kim, Jeongeun Hyun

Clin Mol Hepatol. 2024;30(4):709-713. Published online June 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0412

View: 2100 Download: 83 Web of Science: 1 Crossref: 2

Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis”

Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan

Clin Mol Hepatol. 2024;30(4):649-652. Published online July 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0558

View: 2110 Download: 96 Web of Science: 3 Crossref: 2

Snapshot

Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations

Xinyi Lu, Rui Yang, Yu Chen, Daozhen Chen

Clin Mol Hepatol. 2024;30(3):582-584. Published online December 29, 2023

DOI: https://doi.org/10.3350/cmh.2023.0555

View: 9546 Download: 105

Letter to the Editor

Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia

Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(3):577-579. Published online March 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0157

View: 3002 Download: 171 Web of Science: 9 Crossref: 7

Original Article

Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease

Yiyuan Zheng, Lina Zhao, Zhekun Xiong, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Yugang Fu, Simin Gu, Chong Chen, Jiacheng Li, Yingying Zhu, Jing Liu, Fengbin Liu, Yong Li

Clin Mol Hepatol. 2024;30(3):449-467. Published online April 16, 2024

DOI: https://doi.org/10.3350/cmh.2024.0047

View: 5674 Download: 422 Web of Science: 8 Crossref: 8

Letter to the Editor

Tsubasa Tsutsumi, Dan Nakano, Machiko Kawaguchi, Hirokazu Takahashi, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):266-268. Published online January 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0028

View: 2623 Download: 66 Crossref: 3

Editorial

Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences

Joo Hyun Oh, Dae Won Jun

Clin Mol Hepatol. 2024;30(2):168-170. Published online March 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0140

View: 3219 Download: 95 Web of Science: 4 Crossref: 5

Special Review

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity

Gi-Ae Kim, Joon Ho Moon, Won Kim

Clin Mol Hepatol. 2023;29(4):831-843. Published online August 25, 2023

DOI: https://doi.org/10.3350/cmh.2023.0277

View: 6540 Download: 402 Web of Science: 56 Crossref: 64

Editorial

Risk stratification for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease

Ho Soo Chun, Minjong Lee

Received February 2, 2025 Accepted February 7, 2025

DOI: https://doi.org/10.3350/cmh.2025.0116 [Accepted]

View: 312 Download: 17

Review

Emerging Therapies and Real-World Application of Metabolic Dysfunction-Associated Steatotic Liver Disease Treatment

Hee Yeon Kim, Mary E. Rinella

Received January 22, 2025 Accepted March 30, 2025

DOI: https://doi.org/10.3350/cmh.2025.0083 [Accepted]

View: 468 Download: 63

1 |

Viewed By 8335	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7318	MAFLD: How is it different from NAFLD?
Viewed By 5293	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4950	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4523	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Cited By 319	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 291	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 186	MAFLD: How is it different from NAFLD?
Cited By 101	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 92	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search